Neuromyelitis optica

C. W. Ip; H. Wiendl

doi:10.1055/s-0028-1090039

Aktuelle Neurologie, Table of Contents

Aktuelle Neurologie 2008; 35(9): 450-462
DOI: 10.1055/s-0028-1090039

Fort- und Weiterbildung

Neuromyelitis optica

Neuromyelitis OpticaC. W. Ip, H. Wiendl

Abstract

Full Text

References

Literatur

1 Devic E. Subacute myelitis complicated by optic neuritis [in Französisch]. Bull Med. 1894; 8 1033-1034
2 Devic E. Acute dorsolumbar myelitis with optic neuritis, autopsy [in Französisch]. Congress Francais Medicine. 1895; 1 434-439
3 Albutt T. On the ophtalmoscopic signs of spinal disease. Lancet. 1870; 1 76-88
4 Erb W. Über das Zusammenkommen von Neuritis optica und Myelitis subacuta. Arch Psychiatr Nervenkr. 1879; 1 146-157
5 Phillips P H, Newman N J, Lynn M J. Optic Neuritis in African Americans. Arch Neurol. 1998; 55 186-192
6 Gangopadhyay G, Das S, Sarda P. et al . Clinical profile of multiple sclerosis in Bengal. Neurology India. 1999; 47 18-21
7 Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003; 2 117-127
8 Lau K, Wong L, Li L. et al . Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey. Hong Kong Med J. 2002; 8 77-80
9 Wingerchuk D M, Hogancamp W F, O'Brien P C. et al . The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999; 53 1107-1114
10 Jarius S, Wildemann B. Neuromyelitis optica. Der Nervenarzt. 2007; 78 1365-1377
11 Wingerchuk D, Lennon V, Lucchinetti C. et al . The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6 805-815
12 Wingerchuk D M, Lennon V A, Pittock S J. et al . Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66 1485-1489
13 Jeffery A, Buncic J. Pediatric Devic's neuromyelitis optica. J Pediatr Ophthalmol Strabismus. 1996; 33 223-239
14 Filley C, Sternberg P, Norenberg M. Neuromyelitis optica in the elderly. Arch Neurol. 1984; 41 670-672
15 McKeon A, Lennon V A, Lotze T. et al . CNS aquaporin-4 autoimmunity in children. Neurology. 2008; 71 93-100
16 Weinshenker B, Wingerchuk D, Nakashima I. et al . OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol. 2006; 5 110-111
17 Yamasaki K, Horiuchi I, Minohara M. et al . HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain. 1999; 122 1689-1696
18 Pittock S J, Lennon V A, Krecke K. et al . Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006; 63 390-396
19 Jarius S, Paul F, Franciotta D. et al . Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neuro. 2008; 4 202-214
20 Misu T, Fujihara K, Nakashima I. et al . Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005; 65 1479-1482
21 Wingerchuk D M, Weinshenker B G. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology. 2003; 60 848-853
22 Pittock S, Weinshenker B, Wijdicks E. Mechanical ventilation and tracheostomy in multiple sclerosis. Neurol Neurosurg Psychiatry. 2004; 75 1331-1333
23 Howard R, Wiles C, Hirsch N. et al . Respiratory involvement in multiple sclerosis. Brain. 1992; 115 479-494
24 Pittock S. Neuromyelitis optica brain lesions localized at sites of high aquaporin-4 expression. Arch Neurol. 2006; 63 964-968
25 Vernant J, Cabre P, Smadja D. et al . Recurrent optic neuromyelitis with endocrinopathies: a new syndrome. Neurology. 1997; 48 58-64
26 Wingerchuk D. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007; 68 603-605
27 de Seze J. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci. 2002; 197 57-61
28 Ghezzi A. Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica. J Neurol. 2004; 251 47-52
29 Filippi M, Rocca M. MR imaging of Devic's neuromyelitis optica. Neurol Sci. 2004; 25 371-373
30 Lycklama G. Spinal-cord MRI in multiple sclerosis. Lancet Neurol. 2000; 2 555-562
31 Tartaglino L. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology. 1995; 195 725-732
32 Cabrera-Gomez J A, Quevedo-Sotolongo L, Gonzalez-Quevedo A. et al . Brain magnetic resonance imaging findings in relapsing neuromyelitis optica. Mult Scler. 2007; 13 186-192
33 Poppe A, Lapierre Y, Melançon D. et al . Neuromyelitis optica with hypothalamic involvement. Mult Scler. 2005; 11 617-621
34 Ebers G, Paty D. CSF electrophoresis in one thousand patients. Can J Neurol Sci. 1980; 7 275-280
35 McLean B, Luxton R, Thompson E. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain. 1990; 113 1269-1289
36 O'Riordan J. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996; 60 382-387
37 Bergamaschi R. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler. 2004; 10 2-4
38 Melamud L, Madalena L, Facio M. et al . Cerebrospinal fluid findings in Devic's neuromyelitis optica. Mult Scler. 2006; 12 P246
39 Reiber H. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler. 1998; 4 111-117
40 Meinl E. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol. 2006; 59 880-892
41 Satoh J. Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis. J Neurol Sci. 2003; 212 11-20
42 Lennon V. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364 2106-2112
43 Jarius S. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology. 2007; 68 1076-1077
44 Lennon V. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202 473-477
45 Paul F. Antibody to aquaporin-4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007; 4 e133
46 Nakashima I. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry. 2006; 77 1073-1075
47 Weinstock-Guttman B, Miller C, Yeh E. et al . Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Multiple Sclerosis. 2008; 14 1061-1067
48 Jung J. Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci USA. 1994; 91 13 052-13 056
49 Roemer S F, Parisi J E, Lennon V A. et al . Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007; 130 1194-1205
50 Manley G. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med. 2000; 6 159-163
51 Amiry-Moghaddam M. Delayed K+ clearance associated with aquaporin-4 mislocalization: phenotypic defects in brains of [alpha]-syntrophin-null mice. Proc Natl Acad Sci USA. 2003; 100 13 615-13 620
52 Takahashi T, Fujihara K, Nakashima I. et al . Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007; 130 1235-1243
53 Waters P. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally-extensive transverse myelitis. Arch Neurol. 2008; 65 913-919
54 Lalive P. Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology. 2006; 67 176-177
55 Lucchinetti C F, Mandler R N, McGavern D. et al . A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002; 125 1450-1461
56 Holley J. Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol Appl Neurobiol. 2003; 29 434-444
57 Ayers M. Early glial responses in murine models of multiple sclerosis. Neurochem Int. 2004; 45 409-419
58 Pittock S, Lennon V. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol. 2008; 65 629-632
59 Misu T, Fujihara K, Kakita A. et al . Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007; 130 1224-1234
60 Matiello M, Lennon V A, Jacob A. et al . NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008; 70 2197-2200
61 Paty D, Oger J, Kastrukoff L. et al . MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 1988; 38 180-185
62 Barkhof F, Filippi M, Miller D. et al . Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997; 120 2059-2069
63 Wingerchuk D. Diagnosis and treatment of neuromyelitis optica. Neurologist. 2007; 13 2-11
64 Weinshenker B, Wingerchuk D, Vukusic S. et al . Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006; 59 566-569
65 Jacobi C. Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosus. Lupus. 2006; 15 107-109
66 Weinshenker B, Pittock S, de Seze J. et al . The relationship between neuromyelitis optica and systemic auto-immune disease. Mult Scler. 2006; 12 O79
67 Pittock S, Lennon V, de Seze J. et al . Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008; 65 78-83
68 Wingerchuk D, Weinshenker B. Neuromyelitis optica. Curr Treat Options Neurol. 2008; 10 55-66
69 Beck R W, Cleary P A, Trobe J D. et al . The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple Sclerosis. N Engl J Med. 1993; 329 1764-1769
70 Keegan M, Pineda A A, McClelland R L. et al . Plasma exchange for severe attacks of CNS demyelination: Predictors of response. Neurology. 2002; 58 143-146
71 Papeix C, Vidal J-S, de Seze J. et al . Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Multiple Sclerosis. 2007; 13 256-259
72 Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci. 2007; 252 57-61
73 Saida T, Tashiro K, Itoyama Y. et al . Interferon beta-1b is effective in Japanese RRMS patients: A randomized, multicenter study. Neurology. 2005; 64 621-630
74 Bergamaschi R. Glatiramer acetate treatment in Devic's neuromyelitis optica. Brain. 2003; 126 E1
75 Gartzen K, Limmroth V, Putzki N. Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. Eur J Neurol. 2007; 14 12-13
76 Watanabe S, Misu T, Miyazawa I. et al . Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007; 13 968-974
77 Mandler R. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998; 51 1219-1220
78 Cree B AC, Lamb S, Morgan K. et al . An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 64 1270-1272
79 Jacob A, Weinshenker B G, Violich I. et al . Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients. Arch Neurol. 2008; 65 noc80069
80 Chan A, Weilbach F, Toyka K. et al . Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol. 2005; 139 152-158
81 Neuhaus O, Wiendl H, Kieseier B. et al . Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol. 2005; 1–2 128-137
82 Weinstock-Guttman B, Ramanathan M, Lincoff N. et al . Study of Mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006; 63 957-963
83 Falcini F, Trapani S, Ricci L. et al . Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment. Rheumatology. 2006; 45 913-915
84 Bakker J, Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci. 2004; 31 265-267

Prof. H. Wiendl

Klinische Forschungsgruppe für MS und Neuroimmunologie, Abteilung Neurologie, Universität Würzburg

Josef-Schneider-Str. 11

97080 Würzburg

Email: heinz.wiendl@klinik.uni-wuerzburg.de